Streamlining Biologics Prior Auth in Delaware

The Challenge of Biologics Prior Auth in Delaware

Biologics represent a significant share of specialty drug prior authorizations, impacting specialties from rheumatology and gastroenterology to dermatology and pulmonology. In Delaware, workflows are shaped by state-specific Medicaid managed care organizations and commercial payer footprints. This necessitates a solution that can adapt to varying indication-specific PA criteria, step therapy requirements, and biosimilar substitution policies across multiple plans.

Key Operational Hurdles in Biologics PA Workflows

• **Indication-Specific Criteria:** Matching precise disease states and diagnostic codes from EMRs to payer-specific criteria.
• **Step Therapy Requirements:** Documenting prior-line therapy history, such as csDMARDs for rheumatology or 5-ASA for IBD, to meet payer mandates.
• **Biosimilar Substitution:** Navigating complex payer policies on preferred biosimilars, which vary significantly.
• **Screening Documentation:** Ensuring all required screenings (e.g., TB, hepatitis, immunizations) are documented and current.
• **Periodic Re-authorization:** Managing recurring PA cycles (typically 6-12 months) with updated clinical documentation.
• **Medical vs. Pharmacy Benefit Routing:** Correctly identifying the appropriate benefit channel based on drug administration and payer rules.

Klivira's Automated Approach to Biologics PA in Delaware

Klivira integrates directly with EMRs to automate the intricate steps of biologics prior authorization, reducing manual effort and improving turnaround times. Our platform applies indication-aware step-therapy logic, automates screening documentation, and manages biosimilar substitution routing in alignment with specific payer policies relevant to the Delaware market. This ensures a streamlined process from initial request to re-authorization.

Optimizing Workflows for Delaware's Payer Environment

While specific state-level mandates in Delaware shape the prior authorization landscape, Klivira's platform is designed for adaptability. We connect to a broad network of payer portals and utilize standards like X12 278 and ePA to submit requests efficiently. Our system helps clinics and health systems manage the diverse requirements of commercial and Medicaid managed care plans operating within Delaware, ensuring compliance with general industry benchmarks and best practices.

Core Capabilities for Biologics PA Automation

• **EMR Integration:** Leveraging SMART on FHIR to pull patient data for indication classification and prior therapy history.
• **Policy Library Application:** Dynamically applying payer-specific criteria for TNF inhibitors, IL-17/23, IL-6, and JAK inhibitors.
• **Automated Documentation:** Extracting and populating screening results (TB, Hepatitis B/C, immunizations) directly into PA forms.
• **Re-authorization Management:** Proactively tracking and initiating periodic re-authorization cycles with required clinical updates.
• **Benefit Channel Routing:** Intelligent routing for medical vs. pharmacy benefit claims to reduce denials.

Achieving Operational Excellence in Specialty Biologics

By automating biologics prior auth in Delaware, healthcare organizations can reallocate staff from administrative tasks to patient care. Klivira's evidence-grounded approach helps reduce denial rates, accelerate patient access to critical therapies, and improve the overall efficiency of revenue cycle operations. Our platform is built to support the high-volume demands of specialty pharmacy PA, as recognized by industry benchmarks like the CAQH Index for specialty pharmacy PA volume.